Myriad Genetics' CEO Discusses F2Q12 Results - Earnings Call Transcript

Myriad Genetics, Inc. ( MYGN)

F2Q12 Earnings Call

January 31, 2012 04:30 p.m. ET


Peter D. Meldrum – President and CEO

Mark C. Capone – President, Myriad Genetic Laboratories

James S. Evans – CFO

Rebecca Chambers – Director of IR


Amanda Murphy - William Blair & Company

Jon Wood – Jefferies & Company

Scott Gleason - Stephens Inc.

Michael Yee - RBC Capital Markets

Doug Schenkel - Cowen & Co.

Tycho Peterson – JP Morgan

Isaac Ro - Goldman Sachs & Co.

William Quirk - Piper Jaffray

Dan Leonard - Leerink Swann

Peter Lawson - Mizuho Securities USA Inc.



Ladies and gentlemen, thank you for standing by. Welcome to Myriad Genetics’ Fiscal Second Quarter Earnings Call. (Operator instructions) As a reminder, this conference is being recorded Tuesday, January 31, 2012.

I would now like to turn the conference over to Rebecca Chambers, Director of Investor Relations. Please go ahead, ma’am.

Rebecca Chambers

Thank you, Lindsey. Good afternoon everyone, and welcome to the Myriad Genetics’ Second Fiscal Quarter Earnings Call. During the call we will review the financial results we released today and the progress we have made this quarter on our strategic directives, after which we will host a question-and-answer session. If you have not had a chance to review the earnings release it can be found in the Investor Relations section of our website at

Presenting from Myriad today will be Pete Meldrum, President and Chief Executive Officer; Mark Capone, President, Myriad Genetic Laboratories; and Jim Evans, Chief Financial Officer. This call can be heard live via webcast along with the slide presentation at The call is being recorded and will be archived along with the presentation in the Investor section of our website.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments